How drug resistance takes shape

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Mutations in a hormone receptor can lead to therapeutic resistance by making it less able to bind and respond to hormone blocking drugs and by making it active, even when the hormome is not present.

References Powered by Scopus

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

957Citations
N/AReaders
Get full text

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

901Citations
N/AReaders
Get full text

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

520Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Breast cancer complexity: implications of intratumoral heterogeneity in clinical management

57Citations
N/AReaders
Get full text

Induction of necroptosis in human breast cancer drug-resistant cells by SMAC analog LCL161 after caspase inhibition requires RIP3

14Citations
N/AReaders
Get full text

Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug Resistant Cells

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jeselsohn, R., & Brown, M. (2016). How drug resistance takes shape. ELife, 5(MARCH2016). https://doi.org/10.7554/eLife.14973

Readers over time

‘16‘17‘19‘20‘2100.511.52

Readers' Seniority

Tooltip

Researcher 3

100%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 3

43%

Agricultural and Biological Sciences 2

29%

Medicine and Dentistry 2

29%

Save time finding and organizing research with Mendeley

Sign up for free
0